Sanctions Sought In Discovery Spat V. Mutual Pharma

By Mike Cherney

Law360, New York (September 08, 2009, 4:35 PM ET) -- The plaintiffs in a product liability case against Mutual Pharmaceuticals Co. Inc. over the generic drug sulindac, marketed by Merck & Co. under the brand name Clinoril,

have asked a federal judge to sanction Mutual, alleging it made false statements regarding the availability of years' worth of federally required safety reports regarding the drug.

Attorneys for Karen L. Bartlett and Gregory S. Bartlett filed the motion for sanctions Tuesday in the U.S. District Court for the District of New Hampshire.

In general, the Bartletts allege that...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

Already have access?

  2. Forgot your password?
  4. Sign In

Get instant access to the one-stop news source for business lawyers

Required

Register